Table 3.
Safety data summary.
| Treatment characteristics |
No, N = 61 | Yes, N = 59 |
|---|---|---|
| Chemoimmunotherapy schedule | ||
| •Carboplatin-etoposide-Atezolizumab •Carboplatin-etoposide-Durvalumab •Cisplatin-etoposide-Durvalumab |
60 (98.3%) 1 (1.7%) |
54 (91.5%) 3 (5.1%) 2 (3.4%) |
| Radiotherapy | ||
| •Total radiation dose, fraction, BED: 45 Gy, 2 daily fractions of 1.5 Gy, 51.75 Gy 60 Gy, 2 Gy x 30, 72 Gy 39 Gy, 3 Gy x 13, 50,7 Gy 36 Gy, 3 Gy x 12, 46,8 Gy 50.4 Gy, 2.78 Gy x 18, 63.95 Gy 30 Gy, 3 Gy x 10, 39 Gy 20 Gy, 4 Gy x 5, 28 Gy |
5 (8.5%) 11 (18.6%) 6 (10,2%) 6 (10.2%) 14 (23.7%) 15 (25.4%) 2 (3.4%) |
|